Browse studies

Find your next paid study

45 recruiting studies matching your filters

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE), a Case Collection Registry for 3D Breast Automated Ultrasound Using ATUSA System as Well as Other Breast Imaging Modalities.

AUDIBLE is a multi-site, clinical study conducted in the United States aimed at gathering data on 3D Automated Breast Ultrasound imaging using the iSono Health…

Breast CancerBenign Breast ConditionBreast Fibroadenoma+6 more

Estimated

~$10 – $1,050

iSono Health, Inc.NCT07505797

Phase 3

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatme…

Breast Neoplasms

Estimated

~$10 – $7,500

BioNTech SENCT07173751

Genomic and Non-Genomic Factors Associated With Breast Cancer Risk Factors and Outcomes in a Diverse South Florida Population

The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.

Breast CancerBreast NeoplasmsBreast Diseases

Estimated

~$10 – $750

Memorial Sloan Kettering Cancer CenterNCT06780176

Phase 1

Does Ablation (Cryoablation or Histotripsy) Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotrip…

Metastatic Breast CancerBreast CancerBreast Cancer Stage IV+5 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06246968

Carolina Breast Cancer Study: Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes in the Carolina Breast Cancer Study, Phase 4

Phase 4 of the Carolina Breast Cancer Study (CBCS4) builds on prior phases that examined molecular and epidemiologic differences in breast cancer types and out…

Breast CancerBreast Neoplasms

Estimated

~$10 – $750

UNC Lineberger Comprehensive Cancer CenterNCT07214610

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typicall…

Neoplasms (Cancer / Tumors)Colorectal NeoplasmsLung Neoplasms+8 more

Estimated

~$10 – $1,125

Harvard Medical School (HMS and HSDM)NCT07814872

Phase 2

An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor recepto…

Breast NeoplasmsBreast Cancer

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06797635

Phase 1

Phase 1b/2a Clinical Study of AL58805 Combining With Other Anti-tumor Agents in Advanced, Metastatic GYN, STS or Breast Cancers

This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combination with one of three anticancer treatme…

Endometrial NeoplasmsSoft Tissue Sarcoma (STS)Breast Neoplasms

Estimated

~$10 – $8,750

Advenchen Pharmaceuticals, LLC.NCT07811232

Phase 1

An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain m…

Breast NeoplasmsBrain NeoplasmsNeoplasms by Site+5 more

Estimated

~$10 – $8,750

Stemline Therapeutics, Inc.NCT05386108

Observational

Enhancing Cognitive Function in Breast Cancer Survivors Through Community-based Exercise Training

This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report …

Breast CancerBreast NeoplasmsAnatomic Stage I Breast Cancer AJCC v8+3 more

Estimated

~$10 – $6,250

Mayo ClinicNCT04816006

Phase 1

A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanc…

Ovarian NeoplasmsEndometrial NeoplasmsUterine Cervical Neoplasms+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06400472

Observational

Dissemination of a Breast Reconstruction Decision Tool Through Social Media and Online Communities- AIM1-B

This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants w…

Breast CancerBreast Neoplasms

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07396766